Six homeoproteins directly activate Myod expression in the gene regulatory networks that control early myogenesis

PLoS Genet. 2013 Apr;9(4):e1003425. doi: 10.1371/journal.pgen.1003425. Epub 2013 Apr 25.

Abstract

In mammals, several genetic pathways have been characterized that govern engagement of multipotent embryonic progenitors into the myogenic program through the control of the key myogenic regulatory gene Myod. Here we demonstrate the involvement of Six homeoproteins. We first targeted into a Pax3 allele a sequence encoding a negative form of Six4 that binds DNA but cannot interact with essential Eya co-factors. The resulting embryos present hypoplasic skeletal muscles and impaired Myod activation in the trunk in the absence of Myf5/Mrf4. At the axial level, we further show that Myod is still expressed in compound Six1/Six4:Pax3 but not in Six1/Six4:Myf5 triple mutant embryos, demonstrating that Six1/4 participates in the Pax3-Myod genetic pathway. Myod expression and head myogenesis is preserved in Six1/Six4:Myf5 triple mutant embryos, illustrating that upstream regulators of Myod in different embryonic territories are distinct. We show that Myod regulatory regions are directly controlled by Six proteins and that, in the absence of Six1 and Six4, Six2 can compensate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Gene Regulatory Networks
  • Homeodomain Proteins* / genetics
  • Muscle Development*
  • Transcription Factors / genetics

Substances

  • Homeodomain Proteins
  • Transcription Factors

Grants and funding

The work in MB's laboratory was supported by the Pasteur Institute, the Centre National de la Recherche Scientifique (CNRS), and by grants from the Association Française contre les Myopathies (AFM) and the E.U. networks Optistem (Health FP7-2007-223098) and EuroSyStem (Health FP4-2007-200720). The work in PM's team was supported by the Institut National de la Santé et la Recherche Médicale (INSERM), by grants from the AFM, by the Association de Recherches sur le Cancer (ARC), by the Agence Nationale pour la Recherche (ANR RO5099KK and RPV09108KKA), and by the FP6 MYORES European network of excellence. This work was also supported by funding to FR from INSERM Avenir Program, Association Française contre les Myopathies (AFM), Association Institut de Myologie (AIM), Labex REVIVE, the European Union Sixth and Seventh Framework Program in the project MYORES and ENDOSTEM (grant 241440). CN was supported by a fellowship from the Fondation pour la Recherche Médicale (FRM). The contribution of the Région Ile de France to the Institut Cochin animal care facility is also acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.